Moneycontrol
SENSEX NIFTY
YOU ARE HERE >  Moneycontrol Markets > Announcements Pharmaceuticals

Orchid Pharma

BSE: 524372|NSE: ORCHIDPHAR|ISIN: INE191A01019|SECTOR: Pharmaceuticals
SET ALERT
|
ADD TO PORTFOLIO
|
WATCHLIST
LIVE
BSE
Feb 21, 15:41
16.05
-0.2 (-1.23%)
VOLUME 43,534
LIVE
NSE
Feb 21, 15:53
16.00
-0.25 (-1.54%)
VOLUME 31,259
Announcements on Orchid Pharma

14th-Feb-2018 18:35Source: BSE

Orchid Pharma- Announcement under Regulation 30 (LODR)-Updates

EVALUATION MATRIX FOR RESOLUTION APPLICANTS - UNDER INSOLVENCY AND BANKRUPTCY BOARD OF INDIA (INSOLVENCY RESOLUTION PROCESS FOR CORPORATE PERSONS),REGULATIONS

13th-Feb-2018 10:51Source: BSE

Orchid Pharma- Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for SBICAP Trustee Company Ltd

12th-Feb-2018 10:40Source: BSE

Orchid Pharma- Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Orchid Healthcare Pvt Ltd

9th-Feb-2018 17:26Source: BSE

Orchid Pharma- Announcement under Regulation 30 (LODR)-Updates

FORM G - INVITATION FOR RESOLUTION PLANS UNDER CORPORATE INSOLVENCY RESOLUTION PROCESS

5th-Feb-2018 18:29Source: BSE

Orchid Pharma- Preferential Issue

Intimation regarding the date of receipt of trading approval by Orchid Pharma Ltd upon allotment of 37,02,450 equity shares on preferential basis

19th-Jan-2018 18:21Source: BSE

Orchid Pharma- Updates

INTIMATION UNDER REGULATION 30 OF THE SEBI(LODR) REGULATIONS,2015

19th-Jan-2018 18:06Source: BSE

Orchid Pharma- Shareholding for the Period Ended December 31, 2017

Orchid Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2017. For more details, kindly

16th-Jan-2018 11:51Source: BSE

Orchid Pharma- Statement Of Investor Complaints For The Quarter Ended December 31,2017

Statement of investor complaints for the quarter ended December 31,2017

8th-Jan-2018 15:18Source: NSE

Orchid Pharma Limited

Orchid Pharma Limited has informed the Exchange regarding "Receipt Of Establishment Inspection Report (EIR) From USFDA - Post Marketing Adverse Drug Experience Reporting Inspection (PADE)".

8th-Jan-2018 14:56Source: BSE

Orchid Pharma- Updates

RECEIPT OF ESTABLISHMENT INSPECTION REPORT (EIR)FROM USFDA-POST MARKETING ADVERSE DRUG EXPERIENCE REPORTING INSPECTION(PADE)

1 2 3 4 5 Next >>
Quick Links for Orchid Pharma
Explore Moneycontrol
Stocks     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | Others
Mutual Funds     A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z
Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.